ABT-SLV187

DRUG2 trials

Sponsors

AbbVie (prior sponsor, Abbott), AbbVie

Conditions

Advanced Parkinson's Disease

Phase 2

Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease

CompletedNCT01479127

AbbVie (prior sponsor, Abbott)Advanced Parkinson's Disease

Start: 2011-10-31End: 2012-07-31Updated: 2016-04-21

Phase 3

An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications

CompletedNCT02082249

AbbVieAdvanced Parkinson's Disease

Start: 2014-03-10End: 2019-10-31Updated: 2021-05-12

Related Papers

Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson's disease.

2018-02-268 citations